凯斯特拉医疗科技 KMTS

Brian Webster is our Co-Founder, President and Chief Executive Officer and is a member of our Board. Mr. Webster has served in these roles at Kestra Medical Technologies, Ltd. since 2021 and at Kestra Medical Technologies, Inc. since 2016. Mr. Webster has over 34 years in the medical device industry, including 10 years as President and Chief Executive Officer of Physio-Control, Inc. As a Co-Founder of our Company, Mr. Webster has been building the company as Chief Executive Officer since 2014, when the predecessor company Physio-Control Development Corporation became fully independent from Physio Control Inc., following its acquisition by Bain Capital, LLC in 2012. Mr. Webster previously held executive positions including vice president roles in operations, sales, and marketing at Physio-Control. Mr. Webster brings broad knowledge of emergency medicine, the cardiac field, and the external defibrillation industry. Mr. Webster received his Bachelor of Arts in Business from the University of Puget Sound and his M.B.A. from Seattle University.

Traci S. Umberger is our Co-Founder, General Counsel and Chief Administrative Officer and has been a member of the Board of Kestra Medical Technologies, Ltd. since 2021. She has also been a director of our subsidiary, Kestra Medical Technologies, Inc., since 2016. Ms. Umberger has over 35 years of experience in the life sciences industry, including 10 years as General Counsel and Chief Administrative Officer at Physio-Control, Inc. As a Co-Founder of Kestra, Ms. Umberger has been building the company since 2014, when the predecessor company Physio-Control Development Corporation became fully independent from Physio Control Inc. following its acquisition by Bain Capital, LLC in 2012. Ms. Umberger currently oversees Kestra's Legal, Compliance, and Human Resources functions. Earlier in her career, she practiced in the areas of commercial and healthcare litigation, representing physicians and hospitals. Ms. Umberger received her B.A. in Psychology/English from the University of British Columbia and her J.D. from the University of British Columbia.

Al Ford is our Chief Commercial Officer and has served in this role at Kestra Medical Technologies, Ltd. since 2025. Mr. Ford has over 20 years of experience driving global strategic sales, marketing, business development, product development, and commercial operations primarily within the medical device industry. Mr. Ford served as Chief Commercial Officer of Axonics, Inc. (Nasdaq: AXNX), a medical device company with implantable technologies to treat bladder and bowel disorders, from 2017 to 2025, and Chief Commercial Officer, General Manager and Senior Vice President of Global Sales & Marketing at Cardiac Science Corporation from 2015 to 2017. Mr. Ford received his B.S. in Marketing and his M.S. in International Business from Saint Joseph's University.

Vaseem Mahboob is our Chief Financial Officer and has served in this role at Kestra Medical Technologies, Ltd. since 2021. Mr. Mahboob has over 23 years of finance leadership experience. Prior to joining our company, Mr. Mahboob served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of DIH Technology Ltd. from 2020 to 2021. From 2015 to 2020, Mr. Mahboob served as the Chief Financial Officer of ENDOLOGIX Inc. ENDOLOGIX Inc. filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Northern District of Texas in July 2020. Mr. Mahboob was also a member of the board of directors and the audit committee chair for INSYS Therapeutics from 2018 to 2019. Prior to ENDOLOGIX Inc., Mr. Mahboob held various positions at GE Healthcare, including Chief Financial Officer of the Global Magnetic Resonance Business from 2006 to 2010, Chief Financial Officer of the Global Ultrasound Business from 2010 to 2012, Chief Financial Officer of the Eastern and African Growth Markets from 2013 to 2015 and Chief Financial Officer of GE Healthcare IT from June 2015 to September 2015. Mr. Mahboob received his M.B.A. in Financial Markets and Institutions and Information Systems from the Jacobs School of Management at the State University of New York.

Jeffrey Schwartz is a member of our Board and has served in such role since 2023. He is also the chairman of our Board, a member of our compensation committee and the chair of our nominating and corporate governance committee. Mr. Schwartz currently serves as a Partner and Chief Operating Officer for Global Private Equity at Bain Capital Private Equity, LP. Prior to this role, Mr. Schwartz was a founding member and partner of Bain Capital Life Sciences. Before founding Bain Capital Life Sciences in 2016, he was a leader in the healthcare vertical of Bain Capital Private Equity, LP, where he focused on healthcare investments. Mr. Schwartz previously served on the board of directors of Rapid Micro Biosystems, Inc. (Nasdaq: RPID), SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), and BCLS Acquisition Corp. (a special purpose acquisition company). Mr. Schwartz holds an M.B.A. from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar, and holds a B.A. in economics from Yale University.

Conor Hanley has served as a member of our Board since 2025 and is a member of our audit committee. Mr. Hanley currently serves as the Chief Executive Officer of Foundry Innovation & Research 1, Ltd. (FIRE1). Mr. Hanley brings nearly a decade of distinguished experience in the medical technology industry, with a proven track record of leadership and innovation. Since 2016, he has been an integral member of FIRE1's executive team, where he has played a critical role in advancing the company's mission to revolutionize heart failure management. Mr. Hanley previously worked with ResMed Inc. (ResMed) where he held senior management positions including leading up Chronic Disease management solutions globally, the global Cardiology business unit, and the Ventures and Initiatives global business unit for corporate investments and accelerating new business. Prior to ResMed, Conor was Chief Executive Officer and Co-Founder of BiancaMed, Inc., which was acquired by ResMed in 2011. For over 7 years, he led a team that grew the company through three rounds of venture funding from top-tier international venture funds, launching products in Japan and U.S. (selling to major retailers, including the Apple store) and building the supply chain with mass production in China. Mr. Hanley was awarded a Ph.D. in Chemical Engineering from the University of Pennsylvania, an MBA from INSEAD and a BEng from University College Dublin. Mr. Hanley completed the Leadership4Growth program at Stanford University and is qualified Chartered Director from the Institute of Directors, U.K.

Mary Kay Ladone has been a member of our Board since 2025 and is also the chair of our audit committee and a member of our nominating and corporate governance committee. Additionally, Ms. Ladone was a member of the board of directors of our subsidiary, Kestra Medical Technologies, Inc., from 2022 to 2025. Ms. Ladone is an accomplished executive with over 35 years of experience serving large global healthcare companies. Ms. Ladone served as senior vice president of corporate development, strategy and investor relations at Hill-Rom Holdings, Inc. (Hilrom), a medical technology company, from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president and corporate officer, investor relations of Baxalta, Inc. (formerly NYSE: BXLT), a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc. (NYSE: BAX) (Baxter), and from 1988 to 2015 served in several progressive financial, operational and communication roles at Baxter. Ms. Ladone currently serves on the board of directors of Novanta Inc. (Nasdaq: NOVT), Bioventus LLC (Nasdaq: BVS) and Inogen, Inc. (Nasdaq: INGN). Ms. Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame.

Raymond W. Cohen has been a member of our Board since 2025 and is a member of our audit committee and the chair of our compensation committee. Additionally, Mr. Cohen was a member of the board of directors of our subsidiary, Kestra Medical Technologies, Inc., from 2024 to 2025. Mr. Cohen is an accredited public company director and currently serves on the board, including the audit and compensation committees, of RxSight (Nasdaq: RXST), a medical technology company that makes and markets adjustable intraocular lens to customize vision after cataract surgery. He is the chairman of the board of directors of a number of privately held companies, including Biobeat Technologies, Spiro Medical, Archimedes Vascular, Resonant Link Medical and ExNuero. In addition, Mr. Cohen is also an Operating Partner of the venture fund Star51 Capital as well as a Venture Partner with Andera Partners (Paris) and Sherpa Capital Partners (Beijing). From 2013 to late 2024, Mr. Cohen was the Chief Executive Officer and a member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), a medical device company employing implantable neurostimulation to treat bladder and bowel disorders, during which time he oversaw the company's initial public offering in 2018 and led the company's sale to Boston Scientific Corporation (NYSE: BSX) (Boston Scientific) in late 2024. Mr. Cohen also served as chairman of the board of SoniVie, Ltd., an Israeli medical device company sold to Boston Scientific in May 2025 and Nalu Medical sold to Boston Scientific in October 2025. Earlier in his career, Mr. Cohen served almost a decade as the CEO and Chairman of Cardiac Science, Inc. (formerly NASDAQ: DFIB), a manufacturer of automated external defibrillators, now owned by Zoll Medical. He was also previously the chairman of BioLife Solutions, Inc. (Nasdaq: BLFS) and held board positions at Spectrum Pharmaceuticals (Nasdaq: SPPI) and LifeWatch (LIFE.SW), as well as private companies including Syncroness, Inc. Mr. Cohen received his B.S. in Business Management from Binghamton University.

Kevin Reilly has been a member of our Board since 2025 and is a member of our compensation committee. Additionally, Mr. Reilly was a member of the board of directors of our subsidiary, Kestra Medical Technologies, Inc., from 2024 to 2025. Mr. Reilly has been with Ally Bridge Group since 2021 and is a managing director, head of medtech, for the private equity strategy, focused on transactions across healthcare subsectors. From 2014 to 2021, Mr. Reilly was a principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Mr. Reilly began his career in the Healthcare Investment Banking Group at Stifel. Mr. Reilly received his B.S. in Finance and Information Systems from the University of Maryland.

Elizabeth Kwo, M.D., has served as a member of our Board since 2025 and is a member of our nominating and corporate governance committee. Dr. Kwo currently serves as the President of Vanna Health, Inc. Dr. Kwo has over 20 years of experience as a physician, healthcare executive, entrepreneur, and board leader, scaling digital health platforms and implementing data-driven innovations to improve patient outcomes and reduce costs. Dr. Kwo served as the Chief Commercial Officer of Everly Health, Inc. from 2022 to 2026 and as the Deputy Chief Clinical Officer at Elevance Health, Inc. from 2020 to 2022. Prior to Elevance Health, Inc., Dr. Kwo was the Chief Executive Officer and Co-Founder of InfiniteMD, LLC, which was acquired by ConsumerMedical, an Alight Solutions LLC company, in 2020. Dr. Kwo is Board Certified in Preventive Care and Occupational Medicine and remains active as a practicing physician at Cambridge Health Alliance of Harvard Medical School. She also currently serves on the board of directors of Walmart de Mexico y Centroamerica, Mass General Brigham Innovation, and multiple venture-backed healthcare and medical technology companies. Dr. Kwo received her B.A in human biology from Stanford University, her M.P.H. from Harvard T.H. Chan School of Public Health, her M.D. from Harvard Medical School, and her M.B.A. from Harvard Business School.

Timothy Moran is our Chief Business Officer and has served in this role at Kestra Medical Technologies, Ltd. since 2025. Mr. Moran has over 25 years of experience in the medical device industry. Prior to joining Kestra, Mr. Moran served as President and Chief Executive Officer at Avertix Medical from 2023 until 2025. From 2018 to 2023, he was the Chief Executive Officer of Motus GI Holdings (Nasdaq: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences. Since 2024, he has been a member of the board of directors of Adagio Medical Holdings Inc (Nasdaq: ADGM), and he is chair of the company's compensation committee. Mr. Moran received his B.A. in Organizational Communication at The State University of New York at Geneseo.